实用肝脏病杂志 ›› 2023, Vol. 26 ›› Issue (5): 761-764.doi: 10.3969/j.issn.1672-5069.2023.05.040

• 综述 • 上一篇    下一篇

MicroRNAs作为药物性肝损伤生物标记物研究进展

桂芬芬 综述, 周杰斌 审校   

  1. 421001 湖南省衡阳市 南华大学附属第二医院健康管理中心
  • 收稿日期:2021-09-01 出版日期:2023-09-10 发布日期:2023-09-13
  • 通讯作者: 周杰斌,E-mail:nhdxzjb@sina.com
  • 作者简介:桂芬芬,女,32岁,医学学士,主治医师。主要从事肝脏疾病的超声诊断和临床研究。E-mail:507813040@qq.com

Micro RNAs as biomarkers in patients with drug-induced liver injury

Gui Fenfen, Zhou Jiebin   

  1. Department of Health Management Center, Second Affiliated Hospital, University of South China, Hengyang 421001, Hunan Province, China
  • Received:2021-09-01 Online:2023-09-10 Published:2023-09-13

摘要: 药物性肝损伤(DILI)是全球卫生健康领域的重要挑战和阻碍新药研发的主要障碍之一。DILI缺乏特异性的诊断手段和治疗措施,目前主要依赖早期诊断和对症治疗。本文综述了近年来MicroRNAs作为DILI生物标记物研究取得的重要进展,以期加深对DILI诊断标记物的认识。

关键词: 药物性肝损伤, 微小RNAs, 生物标记物, 诊断

Abstract: Drug-induced liver injury (DILI) is an important challenge to deal with. DILI lacks specific diagnostic parameters and treatment measures, and mainly depends on early diagnosis and supporting treatment. In this article, we reviewed the important achievements on microRNAs study as biomarkers for DILI diagnosis in recent years.

Key words: Drug-induced liver injury, MicroRNAs, Biomarkers, Diagnosis